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tTATE-OF-THE-ART PAPER2251Exercise Testing to Evaluate Valve Hemodynamicsugenio Picano, Philippe Pibarot, Patrizio Lancellotti, Jean Luc Monin, Robert O. Bonow
his state-of-the-art paper by Picano and colleagues reviews the utility of and protocols for
xercise testing in the evaluation of patients with valvular heart disease. As symptoms may
evelop slowly and therefore be unnoticed by patients and their physicians, the symptomatic,
lood pressure, and electrocardiographic responses to exercise can identify patients who would
enefit from valve repair or replacement. The protocols can be tailored for patients with aortic
r mitral valve disease, both before and after valve replacement or repair. The exercise-
nduced changes in valve hemodynamics, ventricular function, and pulmonary artery pressure
rovide the clinician with diagnostic and prognostic information. However, the authors
aution that large-scale prospective randomized studies focusing on patient outcomes are
lacking for many clinical scenarios.JACC WHITE PAPER ACC WHITE PAPER
2261anagement of Antiplatelet Agents in
Patients Undergoing Elective Endoscopic Proceduresichard C. Becker, James Scheiman, Harold L. Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine,
avid A. Johnson, Frances Chan, Neena S. Abraham, Eamonn M. M. Quigley, in collaboration with the
merican College of Cardiology and the American College of Gastroenterology
epresentatives of the American College of Cardiology and the American College of
astroenterology have produced a White Paper designed to aid physicians in the
eriprocedural management of patients taking platelet-directed pharmacotherapy who are
eferred for elective endoscopic gastrointestinal procedures. The paper begins by outlining the
enefits of both aspirin and thienopyridines in various scenarios, including the potential
etrimental effects of sudden drug cessation, particularly in the first 6 months following
ercutaneous coronary intervention with drug-eluting stents (DES). The recommendation is
hat elective endoscopic procedures be deferred if possible for 6 months and possibly up to 12
onths following DES implantation. For procedures that cannot be delayed, particularly
hose associated with heightened bleeding risk, consideration should be given to holding
hienopyridine treatment for 5 to 7 days but continuing aspirin.(continued on page A-31)
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cLINICAL TRIALS2277Infusion of Human Mesenchymal Stem Cells Safe, Possibly Effective, Post-MIoshua M. Hare, Jay H. Traverse, Timothy D. Henry, Nabil Dib, Robert K. Strumpf, Steven P. Schulman,
ary Gerstenblith, Anthony N. DeMaria, Ali E. Denktas, Roger S. Gammon, James B. Hermiller, Jr,
ark A. Reisman, Gary L. Schaer, Warren Sherman
are and colleagues investigated the safety and efficacy of intravenous allogeneic human
esenchymal stem cells (hMSCs) in patients with myocardial infarction (MI). These cells are
ollected from healthy donors rather than the patient; it is believed that they do not generate
n immune response, and thus no human leukocyte antigen-matching is required. This was a
lacebo-controlled, dose-ranging safety trial of intravenous allogeneic hMSCs in 53 post-MI
atients. Adverse event rates were similar between the hMSC- and placebo-treated groups,
nd renal, hepatic, and hematologic laboratory indexes were not different. There were
mprovements in the frequency of ventricular tachycardia episodes and in the ejection fraction
n the subset of anterior MI patients. This trial provides important safety and provisional
fficacy data for allogeneic hMSCs in post-infarction patients.ditorial Comment: Marc S. Penn, Saif Anwaruddin, Ravi Nair, Stephen Ellis, p. 2287NTERVENTIONAL CARDIOLOGY2290Intensive Statin Therapy Particularly Useful in Post-PCI Patients. Michael Gibson, Yuri B. Pride, Claudia P. Hochberg, Sarah Sloan, Marc S. Sabatine,
hristopher P. Cannon, for the TIMI Study Group
ibson and colleagues performed a subgroup analysis of the almost 3,000 subjects in the
ROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–
hrombolysis In Myocardial Infarction 22) trial who underwent percutaneous coronary
ntervention (PCI) prior to randomization. All subjects in the trial presented with an acute
oronary syndrome (ACS), but about one-third did not undergo PCI. Subjects were
andomized to either 80 mg atorvastatin daily or 40 mg pravastatin. Treatment with
torvastatin reduced the incidence of the composite end point (hazard ratio: 0.78) and
owered the incidence of both target vessel revascularization (TVR) and non-TVR. There was
o significant reduction in the primary end point in subjects who had not undergone PCI.
mong patients with ACS who undergo PCI, intensive statin therapy reduces major adverse
ardiac events compared with moderate statin therapy.(continued on page A-32)
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iCUTE MYOCARDIAL INFARCTION2296EMS Transmission of ECGs Improves Door-to-Balloon Times and Outcomesune H. Pedersen, Soren Galatius, Peter R. Hansen, Rasmus Mogelvang, Steen Z. Abildstrom,
ikke Sørensen, Ulla Davidsen, Anders Galloe, Ulrik Abildgaard, Allan Iversen, Jan Bech,
an K. Madsen, Jan S. Jensen
edersen and colleagues reviewed outcomes of almost 1,500 ST-segment elevation myocardial
nfarction (STEMI) patients treated at their institution. The subjects were divided by those
ho had been triaged in the field via wireless transmission of the electrocardiogram (ECG)
rom the emergency medical services (EMS) personnel to a cardiologist at the hospital, and
hose who were triaged after they arrived at the hospital, either the same institution or one
hat required ambulance transfer for primary percutaneous coronary intervention (pPCI).
atients admitted by field triage had a significantly shorter median door-to-balloon time;
oor-to-balloon times 90 min were achieved in nearly two-thirds of field-triaged patients
ut only one-third of nonfield-triaged patients. Patients who were triaged in the field also
ad better clinical outcomes. This study shows that field triage of STEMI patients to pPCI
an significantly reduce door-to-balloon times.ARDIOVASCULAR RISK2303Improved Vascular Risk Prediction With Behavioral and Anthropometric Factorsalph L. Sacco, Minesh Khatri, Tatjana Rundek, Qiang Xu, Hannah Gardener, Bernadette Boden-Albala,
arco R. Di Tullio, Shunichi Homma, Mitchell S. V. Elkind, Myunghee C. Paik
ost of the commonly used cardiovascular risk models were not designed to predict the risk
f stroke, myocardial infarction, or vascular death, which Sacco and colleagues define as global
ascular risk; they also do not include behavioral risk factors or anthropometric measures and
ave lacked ethnic diversity. The NOMAS (Northern Manhattan Study) included significant
roportions of Hispanic and African-American participants. The global vascular risk score
GVRS) was constructed by adding variables to the traditional Framingham cardiovascular
ariables. Variables that significantly added to the traditional Framingham profile included
aist circumference, alcohol consumption, and physical activity. Continuous measures for
lood pressure and fasting blood sugar also seemed to improve accuracy. Ten-year event-free
robabilities ranged from 0.95 for the first quartile of GVRS to 0.56 for the fourth quartile.
he GVRS combines traditional, behavioral, and anthropometric risk factors, uses continuous
ariables for physiological parameters, and is applicable to nonwhite subjects; it appears to
mprove risk stratification.(continued on page A-33)
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EALVULAR HEART DISEASE2312Lateral and Horizontal BAVs Likely Have Different Causesorja Ferna´ndez, Ana C. Dura´n, Teresa Ferna´ndez-Gallego, M. Carmen Ferna´ndez, Miguel Such,
osep M. Arqué, Valentı´n Sans-Coma
icuspid aortic valve (BAV) is the most frequent congenital heart disease, with 2 main
natomical types: laterolateral and anteroposterior. Ferna´ndez and colleagues compared the
mbryonic morphological development of these valves in a strain of mice prone to laterolateral
AV and a strain of hamsters prone to develop anteroposterior BAV. Laterolateral BAVs
esult from a defective development of the outflow tract endocardial cushions, while
nteroposterior BAVs, on the other hand, result from fusion of the right and left conotruncal
idges. These results suggest that laterolateral and anteroposterior BAVs are different
tiological entities and likely are caused by different genetic aberrations.
ditorial Comment: Robert H. Anderson, Robert P. Thompson, Christine B. Kern, p. 2319PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH2321Paclitaxel May Activate Rho-Kinase, Thereby Promoting Vasoconstrictionakashi Shiroto, Satoshi Yasuda, Ryuji Tsuburaya, Yoshitaka Ito, Jun Takahashi, Kenta Ito,
atsue Ishibashi-Ueda, Hiroaki Shimokawa
ome studies suggest that drug-eluting stents (DES) may provoke coronary vasoconstriction
hat is not seen with bare-metal stents. In a series of experiments, Shiroto and colleagues
tudied the effect of paclitaxel on vasoconstriction. The major findings of this study were:
) paclitaxel increased Rho-kinase expression and activity in cultured human coronary artery
mooth muscle cells; 2) paclitaxel-eluting stents enhanced coronary vasoconstriction in
esponse to serotonin in pigs; 3) the constrictive response was abolished by a Rho-kinase
nhibitor; and 4) these functional alterations of the coronary arteries were associated with
nhanced microthrombus formation and inflammatory cell infiltration in areas with increased
ho-kinase activity. These results suggest that the Rho-kinase pathway plays an important
ole in the pathogenesis of DES-induced coronary vasoconstriction.ditorial Comment: Georg Nickenig, Jan-Malte Sinning, p. 2330
